Table 1.

Growth inhibitory effects of steroidal lyase inhibitors against PC-3, DU-145, and LNCaP cells

CompoundCell lineGI50 (μmol/L)95% CI (μmol/L)GI90 (μmol/L)95% CI (μmol/L)
VN/63-1PC-32.911.14–11.57>100
VN/85-11.861.31–2.8630.4113.18–67.61
VN/124-17.827.13–8.3818.6216.10–21.88
VN/125-11.411.22–1.608.076.61–9.80
Abiraterone9.328.69–9.94>100
VN/63-1DU-14511.044.75–22.74>100
VN/85-15.313.71–7.2231.6223.12–40.58
VN/124-17.556.90–8.1115.9513.86–18.24
VN/125-16.575.58–7.5115.5312.40–19.55
Abiraterone14.6813.42–15.95>100
VN/63-1LNCaP1.050.69–1.55>100
VN/85-12.471.55–3.9636.4923.03–58.74
VN/124-13.152.41–4.1731.9923.82–45.01
VN/125-11.180.95–1.4813.469.80–18.01
Abiraterone1.410.95–1.9625.1214.19–100
  • NOTE: Cells were treated with various concentrations of each compound for 96 h, and cell viability was assessed by MTT assay, as described in Materials and Methods. GI50 and GI90 values were calculated from sigmoidal-dose response curves (variable slope) generated from three independent experiments.

  • Abbreviation: 95% CI, 95% confidence interval.